Science China Life Sciences

, Volume 55, Issue 8, pp 677–686 | Cite as

An update on primary ovarian insufficiency

Open Access
Review Special Topic

Abstract

Primary ovarian insufficiency (POI) occurs in about 1% of female population under the age of 40, leading to reproductive problems, an earlier encounter with menopausal symptoms, and complicated diseases. There are three presumable mechanisms involved in the development of POI, namely apoptosis acceleration, follicular maturation blocking and premature follicle activation, through the following studied causes: (i) chromosomal abnormalities or gene mutations: mostly involve X chromosome, such as FMR1 premutation; more and more potentially causal genes have been screened recently; (ii) metabolic disorders such as classic galactosaemia and 17-OH deficiency; (iii) autoimmune mediated ovarian damage: observed alone or with some certain autoimmune disorders and syndromes; but the specificity and sensitivity of antibodies towards ovary are still questionable; (iv) iatrogenic: radiotherapy or chemotherapy used in cancer treatment, as well as pelvic surgery with potential threat to ovaries’ blood supply can directly damage ovarian function; (v) virus infection such as HIV and mumps; (vi) toxins and other environmental/lifestyle factors: cigarette smoking, toxins (e.g., 4-vinylcyclohexene diepoxide), and other environmental factors are associated with the development of POI. The etiology of a majority of POI cases is not identified, and is believed to be multifactorial. Strategies to POI include hormone replacement and infertility treatment. Assisted conception with donated oocytes has been proven to achieve pregnancy in POI women. Embryo cryopreservation, ovarian tissue cryopreservation and oocyte cryopreservation have been used to preserve ovarian reserve in women undergoing cancer treatments.

Keywords

primary ovarian insufficiency genetic aberrations environmental factors hormone replacement therapy ovary preservation 

References

  1. 1.
    Nelson L M. Clinical practice. Primary ovarian insufficiency. N Engl J Med, 2009, 360: 606–614PubMedPubMedCentralGoogle Scholar
  2. 2.
    Cooper A R, Baker V L, Sterling E W, et al. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril, 2011, 95: 1890–1897PubMedPubMedCentralGoogle Scholar
  3. 3.
    van Noord P A, Dubas J S, Dorland M, et al. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril, 1997, 68: 95–102PubMedGoogle Scholar
  4. 4.
    Coulam C B, Adamson S C, Annegers J F. Incidence of premature ovarian failure. Obstet Gynecol, 1986, 67: 604–606PubMedGoogle Scholar
  5. 5.
    Skillern A, Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure. Sex Dev, 2008, 2: 228–243PubMedGoogle Scholar
  6. 6.
    Bachelot A, Rouxel A, Massin N, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol, 2009, 161: 179–187PubMedGoogle Scholar
  7. 7.
    Rebar R W, Erickson G F, Yen S S. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril, 1982, 37: 35–41PubMedGoogle Scholar
  8. 8.
    Rebar R W, Connolly H V. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril, 1990, 53: 804–810PubMedGoogle Scholar
  9. 9.
    Nelson L M, Anasti J N, Kimzey L M, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab, 1994, 79: 1470–1475PubMedGoogle Scholar
  10. 10.
    Bakalov V K, Anasti J N, Calis K A, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril, 2005, 84: 958–965PubMedGoogle Scholar
  11. 11.
    Santoro N. Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab, 2011, 96: 3281–3288PubMedGoogle Scholar
  12. 12.
    Wellons M. Cardiovascular disease and primary ovarian insufficiency. Semin Reprod Med, 2011, 29: 328–341PubMedPubMedCentralGoogle Scholar
  13. 13.
    Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril, 2008, 90: S219–225Google Scholar
  14. 14.
    Younis J S. Ovarian aging and implications for fertility female health. Minerva Endocrinol, 2012, 37: 41–57PubMedGoogle Scholar
  15. 15.
    Goswami D, Conway G S. Premature ovarian failure. Hum Reprod Update, 2005, 11: 391–410PubMedGoogle Scholar
  16. 16.
    Morita Y, Tilly J L. Oocyte apoptosis: like sand through an hourglass. Dev Biol, 1999, 213: 1–17PubMedGoogle Scholar
  17. 17.
    Sullivan S D, Castrillon D H. Insights into primary ovarian insufficiency through genetically engineered mouse models. Semin Reprod Med, 2011, 29: 283–298PubMedGoogle Scholar
  18. 18.
    Adhikari D, Zheng W, Shen Y, et al. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet, 2010, 19: 397–410PubMedPubMedCentralGoogle Scholar
  19. 19.
    Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature, 2004, 428: 145–150PubMedGoogle Scholar
  20. 20.
    van Kasteren Y M, Hundscheid R D, Smits A P, et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod, 1999, 14: 2455–2459PubMedGoogle Scholar
  21. 21.
    Davis C J, Davison R M, Payne N N, et al. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect: opinion. Hum Reprod, 2000, 15: 2418–2422PubMedGoogle Scholar
  22. 22.
    Hunter J E, Epstein M P, Tinker SW, et al. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol, 2008, 32: 553–559PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wittenberger M D, Hagerman R J, Sherman S L, et al. The FMR1 premutation and reproduction. Fertil Steril, 2007, 87: 456–465PubMedGoogle Scholar
  24. 24.
    Murabito J M, Yang Q, Fox C, et al. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab, 2005, 90: 3427–3430PubMedGoogle Scholar
  25. 25.
    Simpson J L. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci, 2008, 1135: 146–154PubMedGoogle Scholar
  26. 26.
    Dixit H, Rao L, Padmalatha V, et al. Genes governing premature ovarian failure. Reprod Biomed Online, 2010, 20: 724–740PubMedGoogle Scholar
  27. 27.
    Zinn A R. The X chromosome and the ovary. J Soc Gynecol Investig, 2001, 8: S34–36PubMedGoogle Scholar
  28. 28.
    Hens L, Devroey P, Van Waesberghe L, et al. Chromosome studies and fertility treatment in women with ovarian failure. Clin Genet, 1989, 36: 81–91PubMedGoogle Scholar
  29. 29.
    Kawano Y, Narahara H, Matsui N, et al. Premature ovarian failure associated with a Robertsonian translocation. Acta Obstet Gynecol Scand, 1998, 77: 467–469PubMedGoogle Scholar
  30. 30.
    Burton K A, Van Ee C C, Purcell K, et al. Autosomal translocation associated with premature ovarian failure. J Med Genet, 2000, 37: E2PubMedPubMedCentralGoogle Scholar
  31. 31.
    Gleicher N, Weghofer A, Kim A, et al. The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve. PLoS ONE, 2012, 7: e33638PubMedPubMedCentralGoogle Scholar
  32. 32.
    Allen E G, Sullivan A K, Marcus M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod, 2007, 22: 2142–2152PubMedGoogle Scholar
  33. 33.
    Murray A, Ennis S, Morton N. No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers. Am J Hum Genet, 2000, 67: 253–254; author reply 256–258PubMedPubMedCentralGoogle Scholar
  34. 34.
    Sullivan A K, Marcus M, Epstein M P, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod, 2005, 20: 402–412PubMedGoogle Scholar
  35. 35.
    Sullivan S D, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med, 2011, 29: 299–307PubMedGoogle Scholar
  36. 36.
    Allen E G, He W, Yadav-Shah M, et al. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet, 2004, 114: 439–447PubMedGoogle Scholar
  37. 37.
    Bretherick K L, Fluker M R, Robinson W P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet, 2005, 117: 376–382PubMedGoogle Scholar
  38. 38.
    Bretherick K L, Hanna C W, Currie L M, et al. Estrogen receptor alpha gene polymorphisms are associated with idiopathic premature ovarian failure. Fertil Steril, 2008, 89: 318–324PubMedGoogle Scholar
  39. 39.
    Vujovic S. Aetiology of premature ovarian failure. Menopause Int, 2009, 15: 72–75PubMedGoogle Scholar
  40. 40.
    Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev, 2011, 78: 9–21PubMedPubMedCentralGoogle Scholar
  41. 41.
    McNatty K P, Juengel J L, Reader K L, et al. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function in ruminants. Reproduction, 2005, 129: 481–487PubMedGoogle Scholar
  42. 42.
    Dube J L, Wang P, Elvin J, et al. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol, 1998, 12: 1809–1817PubMedGoogle Scholar
  43. 43.
    Aaltonen J, Laitinen M P, Vuojolainen K, et al. Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9B are expressed in oocytes during early folliculogenesis. J Clin Endocrinol Metab, 1999, 84: 2744–2750PubMedGoogle Scholar
  44. 44.
    Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet, 2004, 75: 106–111PubMedPubMedCentralGoogle Scholar
  45. 45.
    Di Pasquale E, Rossetti R, Marozzi A, et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab, 2006, 91: 1976–1979PubMedGoogle Scholar
  46. 46.
    Dixit H, Rao L K, Padmalatha V V, et al. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet, 2006, 119: 408–415PubMedGoogle Scholar
  47. 47.
    Laissue P, Christin-Maitre S, Touraine P, et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol, 2006, 154: 739–744PubMedGoogle Scholar
  48. 48.
    Zhao Z Z, Painter J N, Palmer J S, et al. Variation in bone morphogenetic protein 15 is not associated with spontaneous human dizygotic twinning. Hum Reprod, 2008, 23: 2372–2379PubMedPubMedCentralGoogle Scholar
  49. 49.
    Inagaki K, Shimasaki S. Impaired production of BMP-15 and GDF-9 mature proteins derived from proproteins WITH mutations in the proregion. Mol Cell Endocrinol, 2010, 328: 1–7PubMedPubMedCentralGoogle Scholar
  50. 50.
    Spicer L J, Aad P Y, Allen D T, et al. Growth differentiation factor 9 (GDF9) stimulates proliferation and inhibits steroidogenesis by bovine theca cells: influence of follicle size on responses to GDF9. Biol Reprod, 2008, 78: 243–253PubMedGoogle Scholar
  51. 51.
    Orisaka M, Tajima K, Tsang B K, et al. Oocyte-granulosa-theca cell interactions during preantral follicular development. J Ovarian Res, 2009, 2: 9PubMedPubMedCentralGoogle Scholar
  52. 52.
    Dong J, Albertini D F, Nishimori K, et al. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature, 1996, 383: 531–535PubMedGoogle Scholar
  53. 53.
    Huang Q, Cheung A P, Zhang Y, et al. Effects of growth differentiation factor 9 on cell cycle regulators and ERK42/44 in human granulosa cell proliferation. Am J Physiol Endocrinol Metab, 2009, 296: E1344–1353PubMedGoogle Scholar
  54. 54.
    Galloway S M, McNatty K P, Cambridge L M, et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet, 2000, 25: 279–283PubMedGoogle Scholar
  55. 55.
    Hanrahan J P, Gregan S M, Mulsant P, et al. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod, 2004, 70: 900–909PubMedGoogle Scholar
  56. 56.
    Nicol L, Bishop S C, Pong-Wong R, et al. Homozygosity for a single base-pair mutation in the oocyte-specific GDF9 gene results in sterility in Thoka sheep. Reproduction, 2009, 138: 921–933PubMedGoogle Scholar
  57. 57.
    Montgomery G W, Zhao Z Z, Marsh A J, et al. A deletion mutation in GDF9 in sisters with spontaneous DZ twins. Twin Res, 2004, 7: 548–555PubMedGoogle Scholar
  58. 58.
    Palmer J S, Zhao Z Z, Hoekstra C, et al. Novel variants in growth differentiation factor 9 in mothers of dizygotic twins. J Clin Endocrinol Metab, 2006, 91: 4713–4716PubMedGoogle Scholar
  59. 59.
    Pisarska M D, Kuo F T, Bentsi-Barnes I K, et al. LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity. Am J Physiol Endocrinol Metab, 2010, 299: E101–109PubMedPubMedCentralGoogle Scholar
  60. 60.
    Matthews C H, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet, 1993, 5: 83–86PubMedGoogle Scholar
  61. 61.
    Aittomaki K, Lucena J L, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell, 1995, 82: 959–968PubMedGoogle Scholar
  62. 62.
    Liu J Y, Gromoll J, Cedars M I, et al. Identification of allelic variants in the follicle-stimulating hormone receptor genes of females with or without hypergonadotropic amenorrhea. Fertil Steril, 1998, 70: 326–331PubMedGoogle Scholar
  63. 63.
    Takahashi K, Ozaki T, Okada M, et al. Increased prevalence of luteinizing hormone beta-subunit variant in patients with premature ovarian failure. Fertil Steril, 1999, 71: 96–101PubMedGoogle Scholar
  64. 64.
    Lofrano-Porto A, Barra G B, Giacomini L A, et al. Luteinizing hormone beta mutation and hypogonadism in men and women. N Engl J Med, 2007, 357: 897–904PubMedGoogle Scholar
  65. 65.
    Latronico A C, Chai Y, Arnhold I J, et al. A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor. Mol Endocrinol, 1998, 12: 442–450PubMedGoogle Scholar
  66. 66.
    Chand A L, Harrison C A, Shelling A N. Inhibin and premature ovarian failure. Hum Reprod Update, 2010, 16: 39–50PubMedGoogle Scholar
  67. 67.
    Prakash G J, Ravi Kanth V V, Shelling A N, et al. Mutational analysis of inhibin alpha gene revealed three novel variations in Indian women with premature ovarian failure. Fertil Steril, 2010, 94: 90–98PubMedGoogle Scholar
  68. 68.
    MacNaughton J, Banah M, McCloud P, et al. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol (Oxf), 1992, 36: 339–345Google Scholar
  69. 69.
    Petraglia F, Hartmann B, Luisi S, et al. Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea. Fertil Steril, 1998, 70: 907–912PubMedGoogle Scholar
  70. 70.
    Soules M R, Battaglia D E, Klein N A. Inhibin and reproductive aging in women. Maturitas, 1998, 30: 193–204PubMedGoogle Scholar
  71. 71.
    Waggoner D D, Buist N R, Donnell G N. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis, 1990, 13: 802–818PubMedGoogle Scholar
  72. 72.
    Schuh-Huerta S M, Johnson N A, Rosen M P, et al. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod, 2012, 27: 594–608PubMedPubMedCentralGoogle Scholar
  73. 73.
    Christin-Maitre S, Pasquier M, Donadille B, et al. Premature ovarian failure. Ann Endocrinol (Paris), 2006, 67: 557–566Google Scholar
  74. 74.
    Cordts E B, Christofolini D M, Dos Santos A A, et al. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet, 2011, 283: 635–643PubMedGoogle Scholar
  75. 75.
    Forges T, Monnier-Barbarino P, Leheup B, et al. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update, 2006, 12: 573–584PubMedGoogle Scholar
  76. 76.
    Kaufman F R, Kogut M D, Donnell G N, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med, 1981, 304: 994–998PubMedGoogle Scholar
  77. 77.
    Rubio-Gozalbo M E, Gubbels C S, Bakker J A, et al. Gonadal function in male and female patients with classic galactosemia. Hum Reprod Update, 2010, 16: 177–188PubMedGoogle Scholar
  78. 78.
    Levy H L. Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. Turk J Pediatr, 1996, 38: 335–344PubMedGoogle Scholar
  79. 79.
    Gubbels C S, Kuppens S M, Bakker J A, et al. Pregnancy in classic galactosemia despite undetectable anti-Mullerian hormone. Fertil Steril, 2009, 91: 1293–1296PubMedGoogle Scholar
  80. 80.
    Sanders R D, Spencer J B, Epstein M P, et al. Biomarkers of ovarian function in girls and women with classic galactosemia. Fertil Steril, 2009, 92: 344–351PubMedPubMedCentralGoogle Scholar
  81. 81.
    Gubbels C S, Thomas C M, Wodzig W K, et al. FSH isoform pattern in classic galactosemia. J Inherit Metab Dis, 2011, 34: 387–390PubMedPubMedCentralGoogle Scholar
  82. 82.
    Hoek A, Schoemaker J, Drexhage H A. Premature ovarian failure and ovarian autoimmunity. Endocr Rev, 1997, 18: 107–134PubMedGoogle Scholar
  83. 83.
    Smith J A, Vitale S, Reed G F, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol, 2004, 122: 151–156PubMedGoogle Scholar
  84. 84.
    Husebye E S, Lovas K. Immunology of Addison’s disease and premature ovarian failure. Endocrinol Metab Clin North Am, 2009, 38: 389–405PubMedGoogle Scholar
  85. 85.
    Cheng M H, Nelson L M. Mechanisms and models of immune tolerance breakdown in the ovary. Semin Reprod Med, 2011, 29: 308–316PubMedGoogle Scholar
  86. 86.
    La Marca A, Brozzetti A, Sighinolfi G, et al. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol, 2010, 22: 277–282PubMedGoogle Scholar
  87. 87.
    Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med, 2002, 11: 585–599PubMedGoogle Scholar
  88. 88.
    Dragojevic-Dikic S, Marisavljevic D, Mitrovic A, et al. An immunological insight into premature ovarian failure (POF). Autoimmun Rev, 2010, 9: 771–774PubMedGoogle Scholar
  89. 89.
    Donnez J, Dolmans M M, Pirard C, et al. Allograft of ovarian cortex between two genetically non-identical sisters: case report. Hum Reprod, 2007, 22: 2653–2659PubMedGoogle Scholar
  90. 90.
    Howard-Anderson J, Ganz P A, Bower J E, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst, 2012, 104: 386–405PubMedGoogle Scholar
  91. 91.
    Fleischer R T, Vollenhoven B J, Weston G C. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv, 2011, 66: 248–254PubMedGoogle Scholar
  92. 92.
    Clowse M E, Behera M A, Anders C K, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt), 2009, 18: 311–319Google Scholar
  93. 93.
    Meirow D, Biederman H, Anderson R A, et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol, 2010, 53: 727–739PubMedGoogle Scholar
  94. 94.
    Nicosia S V, Matus-Ridley M, Meadows A T. Gonadal effects of cancer therapy in girls. Cancer, 1985, 55: 2364–2372PubMedGoogle Scholar
  95. 95.
    Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod, 2007, 22: 1626–1633PubMedGoogle Scholar
  96. 96.
    Read M D, Edey K A, Hapeshi J, et al. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int, 2010, 16: 56–59PubMedGoogle Scholar
  97. 97.
    Amato P, Roberts A C. Transient ovarian failure: a complication of uterine artery embolization. Fertil Steril, 2001, 75: 438–439PubMedGoogle Scholar
  98. 98.
    Api M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol, 2009, 25: 159–165PubMedGoogle Scholar
  99. 99.
    Prinz W, Taubert H D. Mumps in pubescent females and its effect on later reproductive function. Gynaecologia, 1969, 167: 23–27PubMedGoogle Scholar
  100. 100.
    Morrison J C, Givens J R, Wiser W L, et al. Mumps oophoritis: a cause of premature menopause. Fertil Steril, 1975, 26: 655–659PubMedGoogle Scholar
  101. 101.
    Cejtin H E, Kalinowski A, Bacchetti P, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol, 2006, 108: 1423–1431PubMedGoogle Scholar
  102. 102.
    Ohl J, Partisani M, Demangeat C, et al. Alterations of ovarian reserve tests in Human Immunodeficiency Virus (HIV)-infected women. Gynecol Obstet Fertil, 2010, 38: 313–317PubMedGoogle Scholar
  103. 103.
    Hoyer P B, Devine P J, Hu X, et al. Ovarian toxicity of 4-vinylcyclohexene diepoxide: a mechanistic model. Toxicol Pathol, 2001, 29: 91–99PubMedGoogle Scholar
  104. 104.
    Christin-Maitre S, Ronci-Chaix N, Bouchard P. Ovary genes and molecular pathology. J Soc Biol, 2002, 196: 207–216PubMedGoogle Scholar
  105. 105.
    De Miguel M P, Cheng L, Holland E C, et al. Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci USA, 2002, 99: 10458–10463PubMedPubMedCentralGoogle Scholar
  106. 106.
    Kappeler C J, Hoyer P B. 4-vinylcyclohexene diepoxide: a model chemical for ovotoxicity. Syst Biol Reprod Med, 2012, 58: 57–62PubMedPubMedCentralGoogle Scholar
  107. 107.
    Di Prospero F, Luzi S, Iacopini Z. Cigarette smoking damages women’s reproductive life. Reprod Biomed Online, 2004, 8: 246–247PubMedGoogle Scholar
  108. 108.
    Chang S H, Kim C S, Lee K S, et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas, 2007, 58: 19–30PubMedGoogle Scholar
  109. 109.
    Kinney A, Kline J, Kelly A, et al. Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod, 2007, 22: 1175–1185PubMedGoogle Scholar
  110. 110.
    Nardo L G, Christodoulou D, Gould D, et al. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol, 2007, 23: 486–493PubMedGoogle Scholar
  111. 111.
    Matikainen T, Perez G I, Jurisicova A, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet, 2001, 28: 355–360PubMedGoogle Scholar
  112. 112.
    Sharara F I, Seifer D B, Flaws J A. Environmental toxicants and female reproduction. Fertil Steril, 1998, 70: 613–622PubMedGoogle Scholar
  113. 113.
    Klein P, Serje A, Pezzullo J C. Premature ovarian failure in women with epilepsy. Epilepsia, 2001, 42: 1584–1589PubMedGoogle Scholar
  114. 114.
    Testa G, Chiaffarino F, Vegetti W, et al. Case-control study on risk factors for premature ovarian failure. Gynecol Obstet Invest, 2001, 51: 40–43PubMedGoogle Scholar
  115. 115.
    Proetto Menopausa Italia Study Group, et al. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clinics in Italy. BJOG, 2003, 110: 59–63Google Scholar
  116. 116.
    Henzl M R, Loomba P K. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med, 2003, 48: 525–540PubMedGoogle Scholar
  117. 117.
    Jones S C. Subcutaneous estrogen replacement therapy. J Reprod Med, 2004, 49: 139–142PubMedGoogle Scholar
  118. 118.
    Nelson H D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA, 2004, 291: 1610–1620PubMedGoogle Scholar
  119. 119.
    Popat V B, Vanderhoof V H, Calis K A, et al. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril, 2008, 89: 429–433PubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  1. 1.Women’s Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations